What is Sotrovimab? The New COVID-19 Treatment

Publish date: Sunday، 05 December 2021

The world is still combatting Covid-19 which has been declared as a pandemic early 2020. Countries may have been successful in the fight as vaccinations rolled out, but they're still not a cure. A new treatment has been introduced, Sotrovimab (Vir-7831), and we are here to tell you all about it.

Then Sotrovimab is an investigational SARS-CoV-2 monoclonal antibody. Preclinical data suggest it has the potential to both block viral entry into healthy cells and clear infected cells.

“Sotrovimab-VIR-7831” depends on “monoclonal antibodies” to treat patients aged 12 years and over who face a high risk of developing severe symptoms and hospitalization due to the repercussions of the disease.

The approval of a new drug that studies have proven effective in treating the mutated virus and the emerging mutations from it and helps in speeding up the healing of the infected and reducing deaths among COVID-19 patients represents a positive development in the ongoing battle against the virus.

It is also FDA approved as it is said to reduce the number of cases requiring admission to hospital for more than 24 hours and reducing the number of deaths due to infection with the virus by up to 85 percent when given to patients as an early treatment.

This is great news as it only means that we all are slowly reaching the finish line of fighting Covid-19 and getting back sooner to our normal lives pre-covid.

Image Source: Unsplash

This article was previously published on UAE Moments.To see the original article, click here

To read the full story for free, please enter your e-mail

Thank you for your subscription, you will receive our Newsletter shortly

What is Sotrovimab? The New COVID-19 Treatment

Related articles